Daily News Podcast

Rivaroxaban data abound at ESC 2018

Publish date: August 28, 2018

 

New results from the ASCEND trial show that neither aspirin nor fish oil provides any net clinical benefit for primary cardiovascular prevention in patients with diabetes. Also today, rivaroxaban is no help for heart failure outcomes, VTE risk is unchanged by rivaroxaban taken after discharge, and the AAP cautions against marijuana use during pregnancy and breastfeeding. Subscribe to the MDedge Daily News wherever you get your podcasts.

Amazon Alexa
Apple Podcasts
Spotify

Recommended Reading

French warn of upsurge in pneumococcal meningitis
MDedge Infectious Disease
Variation doesn’t mean quality when it comes to diet
MDedge Infectious Disease
Medicare Advantage pushback
MDedge Infectious Disease
Psoriasis registry study provides more data on infliximab’s infection risk
MDedge Infectious Disease
Open AAA and peripheral bypass surgery patients among the highest users of post-acute care
MDedge Infectious Disease
Sleepio app tied to reducing insomnia, depression
MDedge Infectious Disease
5 digital HIPAA myths
MDedge Infectious Disease
Screen for cervical cancer based on age, risk
MDedge Infectious Disease
Is it time for PCPs to take over chronic HCV?
MDedge Infectious Disease
Lorcaserin shows cardiovascular safety
MDedge Infectious Disease